Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Association of molecular marker O(6)Methylguanine DNA methyltransferase and concomitant chemoradiotherapy with survival in Southern Chinese glioblastoma patients.

Chan DT, Kam MK, Ma BB, Ng SC, Pang JC, Lau CK, Siu DY, Ng BS, Zhu XL, Chen GG, Ng HK, Poon WS.

Hong Kong Med J. 2011 Jun;17(3):184-8.

2.

Pseudoprogression of malignant glioma in Chinese patients receiving concomitant chemoradiotherapy.

Chan DT, Ng RY, Siu DY, Tang P, Kam MK, Ma BB, Wong GK, Ng SC, Pang JC, Lau CK, Zhu XL, Ng HK, Poon WS.

Hong Kong Med J. 2012 Jun;18(3):221-5.

3.

O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.

Lechapt-Zalcman E, Levallet G, Dugué AE, Vital A, Diebold MD, Menei P, Colin P, Peruzzy P, Emery E, Bernaudin M, Chapon F, Guillamo JS.

Cancer. 2012 Sep 15;118(18):4545-54. doi: 10.1002/cncr.27441. Epub 2012 Feb 22.

4.

MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.

Gutenberg A, Bock HC, Brück W, Doerner L, Mehdorn HM, Roggendorf W, Westphal M, Felsberg J, Reifenberger G, Giese A.

Br J Neurosurg. 2013 Dec;27(6):772-8. doi: 10.3109/02688697.2013.791664. Epub 2013 May 11.

PMID:
23662801
5.

Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.

Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M.

Cancer. 2009 Aug 1;115(15):3512-8. doi: 10.1002/cncr.24406.

6.
7.

Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.

Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F.

Clin Neurol Neurosurg. 2015 May;132:1-8. doi: 10.1016/j.clineuro.2015.01.029. Epub 2015 Feb 7.

PMID:
25723791
8.
9.

A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival.

Abhinav K, Aquilina K, Gbejuade H, La M, Hopkins K, Iyer V.

Clin Neurol Neurosurg. 2013 Aug;115(8):1375-8. doi: 10.1016/j.clineuro.2012.12.023. Epub 2013 Jan 18.

PMID:
23333005
10.

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, Steinbach JP, Hundsberger T, Wick W, Meyermann R, Tan TC, Sommer C, Bamberg M, Reifenberger G, Weller M.

J Clin Oncol. 2006 Sep 20;24(27):4412-7.

PMID:
16983109
11.

Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.

Kim YH, Kim T, Joo JD, Han JH, Kim YJ, Kim IA, Yun CH, Kim CY.

Cancer. 2015 Sep 1;121(17):2926-32. doi: 10.1002/cncr.29439. Epub 2015 May 14.

12.

Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.

Costa BM, Caeiro C, Guimarães I, Martinho O, Jaraquemada T, Augusto I, Castro L, Osório L, Linhares P, Honavar M, Resende M, Braga F, Silva A, Pardal F, Amorim J, Nabiço R, Almeida R, Alegria C, Pires M, Pinheiro C, Carvalho E, Lopes JM, Costa P, Damasceno M, Reis RM.

Oncol Rep. 2010 Jun;23(6):1655-62.

PMID:
20428822
13.
14.

High-mobility group AT-hook protein 2 expression and its prognostic significance in MGMT methylated and unmethylated glioblastoma.

Schwarm FP, Uhle F, Schänzer A, Acker T, Stein M, Reinges MH, Weischer C, Weigand MA, Uhl E, Kolodziej MA.

Int J Oncol. 2016 Apr;48(4):1485-92. doi: 10.3892/ijo.2016.3397. Epub 2016 Feb 17.

PMID:
26892260
15.

O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.

Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, Calbucci F, Ermani M.

Neuro Oncol. 2010 Mar;12(3):283-8. doi: 10.1093/neuonc/nop050. Epub 2010 Feb 1.

16.

O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.

Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T.

Int J Clin Oncol. 2010 Aug;15(4):352-8. doi: 10.1007/s10147-010-0065-6. Epub 2010 Mar 16.

PMID:
20232102
17.

Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy.

Kreth FW, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T, Weller M, Tonn JC; German Glioma Network..

Ann Oncol. 2013 Dec;24(12):3117-23. doi: 10.1093/annonc/mdt388. Epub 2013 Oct 14.

PMID:
24130262
18.

Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.

Eoli M, Menghi F, Bruzzone MG, De Simone T, Valletta L, Pollo B, Bissola L, Silvani A, Bianchessi D, D'Incerti L, Filippini G, Broggi G, Boiardi A, Finocchiaro G.

Clin Cancer Res. 2007 May 1;13(9):2606-13.

19.

Survival in patients with newly diagnosed conventional glioblastoma: a modified prognostic score based on a single-institution series.

Bertolini F, Zunarelli E, Baraldi C, Valentini A, Del Giovane C, Depenni R, Falasca A, Giacobazzi P, Malagoli M, Meletti S, Fontana A, Conte P; Gruppo Neuro Oncologico Modena (GNO-MO)..

Tumori. 2012 Nov;98(6):756-61. doi: 10.1700/1217.13500.

PMID:
23389363
20.

Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.

Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY.

Neuro Oncol. 2008 Jun;10(3):300-8. doi: 10.1215/15228517-2008-005. Epub 2008 Apr 10.

Supplemental Content

Support Center